Diomed completes 1-to-25 reverse split stock:
This article was originally published in Clinica
Executive Summary
Diomed has reduced its number of outstanding shares from 365 million to 14.6 million, following the completion of a 1-to-25 reverse split stock. According to Diomed president and CEO, James Wylie, the move should bring the share price of the Andover, Massachusetts company share into a range that is more acceptable to both retail and institutional investors. Diomed's first quarter results for 2004 showed a 39% increase in revenues over Q1 2003. Revenues generated by its endovenous laser treatment (EVLT) for varicose veins increased 53% over the same period last year. Diomed owns exclusive rights to the patent covering its EVLT procedure which was cleared by the FDA in January 2002.
You may also be interested in...
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.